Peringkat dalam Saham
#28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Harga Saham
$0.07339369
Terakhir disinkronkan: 2026-08-18
Kapitalisasi Pasar
$25.24M
Perubahan (1 tahun)
-9.55%
Perdagangan Resverlogix Corp. (RVX)
Harga RVX dengan kapitalisasi pasar B
Kapitalisasi pasar dari Resverlogix Corp.(RVX)
Kapitalisasi Pasar: $25.24M
Per August 2026, Resverlogix Corp. memiliki kapitalisasi pasar sebesar $25.24M. Ini menjadikan Resverlogix Corp. sebagai perusahaan 28673rd paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Resverlogix Corp. dari 2004 hingga 2026
RVX dibandingkan dengan 5 teratas stocks paling populer
| Harga RVX |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.301T
|
+20,999,338.36%
|
|
|
|
|
$4.634T
|
+18,357,012.00%
|
|
|
|
|
$4.143T
|
+16,412,357.35%
|
|
|
|
|
$3.589T
|
+14,219,233.93%
|
|
|
|
|
$2.857T
|
+11,317,728.88%
|
